ArticleBMJ neurology open2026
Deep brain stimulation battery longevity: a cohort study comparing impact of anaesthesia modality and anatomic target.
Article in BMJ neurology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Deep brain stimulation (DBS) treats various movement disorders, though routine battery replacement is required. Factors affecting battery life remain unclear; prior studies implicate programming parameters and device model. Advancements in intraoperative guidance enable DBS placement under general anaesthesia (GA) using direct targeting instead of conscious sedation (Monitored anesthesia care or MAC) using indirect targeting. This study examines the effect of DBS anaesthesia type on IPG battery longevity and other influencing factors. Methods: Retrospective chart review of 254 patients who underwent DBS placement between 2013 and 2023 at a tertiary care centre was completed under an IRB-approved protocol, 217 of whom met inclusion criteria. Using an accelerated failure time (AFT) model, battery longevity was assessed as a function of anaesthesia type, electrode location, stimulation parameters, diagnosis, demographics, Movement Disorder Society Unified Parkinson's Disease Rating Scale part III score (MDS-UPDRS-III) and battery type. Results: DBS implanted with MAC resulted in significantly reduced battery longevity, AFT coefficient=-0.149, 95% CI -0.27 to -0.03 (p<0.05) compared with GA. compared with globus pallidus interna, subthalamic nucleus implantation (AFT coefficient=0.223, 95% CI 0.10 to 0.35, p<0.05) and thalamic ventral intermediate nucleus (VIM) implantation (AFT coefficient=0.134, 95% CI 0.01 to 0.26, p<0.05) were associated with significantly longer battery longevity. High amplitude settings significantly reduced battery longevity, AFT coefficient=-0.167, 95% CI -0.21 to -0.12 (p<0.05). Diagnosis, MDS-UPDRS-III score and battery model effects on IPG battery longevity were not statistically significant. Conclusion: Battery longevity can be optimised by considering anaesthesia type and electrode location during implantation. Improved battery longevity reduces replacement frequency, associated complications and overall healthcare costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.